Wednesday, July 8, 2026

biotech · Moderately to Severely Active Ulcerative Colitis · Inflammatory Bowel Diseases · ODTX

Odyssey Therapeutics

Odyssey Therapeutics clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

San Ramon, USA HQ
3 Employees
Public company Type
ODTX · NYSE Ticker
Company details
Status
Public
HQ
San Ramon, USA
Employees
3
Programs
4
Drugs
6
Patents
1
Intelligence · Clinical Programs

Odyssey Therapeutics projects

2 ClinicalTrials.gov programs sponsored by Odyssey Therapeutics.

Odyssey Therapeutics has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. OD-07656

    Odyssey Therapeutics

    Ulcerative Colitis (UC)

    phase 2 small molecule active

    1 trial
  2. OD-07656-201

    Odyssey Therapeutics

    Moderately to Severely Active Ulcerative Colitis

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Odyssey Therapeutics have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.